1438 related articles for article (PubMed ID: 8760593)
1. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
Thibault C; Nelson H; Chapoval AI
Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody.
Penna C; Dean PA; Nelson H
Int J Cancer; 1996 Jan; 65(3):377-82. PubMed ID: 8575861
[TBL] [Abstract][Full Text] [Related]
4. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application.
Chapoval AI; Nelson H; Thibault C; Penna C; Dean P
J Hematother; 1995 Dec; 4(6):571-7. PubMed ID: 8846018
[TBL] [Abstract][Full Text] [Related]
5. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
[TBL] [Abstract][Full Text] [Related]
6. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
McConnell EJ; McLemore EC; Talac R; Joshi L; Nelson H
J Surg Res; 2004 Nov; 122(1):103-12. PubMed ID: 15522322
[TBL] [Abstract][Full Text] [Related]
7. The bispecific antibody 500A2 x 96.5 targets T-lymphocytes activated in vivo with staphylococcal enterotoxin B (SEB) against CL62 melanoma cells in vitro.
Reid IM; Lundy JK; Donohue JH
Surg Oncol; 1994 Oct; 3(5):279-85. PubMed ID: 7889221
[TBL] [Abstract][Full Text] [Related]
8. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
Penna C; Dean PA; Nelson H
Cancer Res; 1994 May; 54(10):2738-43. PubMed ID: 8168104
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
10. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
11. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
Belani R; Weiner GJ
J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
Reid I; Lundy J; Donohue JH
J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
[TBL] [Abstract][Full Text] [Related]
13. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
14. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
Tutt AL; Reid R; Wilkins BS; Glennie MJ
J Immunol; 1995 Sep; 155(6):2960-71. PubMed ID: 7673714
[TBL] [Abstract][Full Text] [Related]
15. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
16. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
17. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
Eissler N; Ruf P; Mysliwietz J; Lindhofer H; Mocikat R
Cancer Res; 2012 Aug; 72(16):3958-66. PubMed ID: 22745368
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
19. Superantigen-activated T cells redirected by a bispecific antibody inhibit vesicular stomatitis virus replication in vitro and in vivo.
Fernandez-Sesma A; Peluso RW; Bai X; Schulman JL; Levy DE; Moran TM
J Immunol; 1998 Feb; 160(4):1841-9. PubMed ID: 9469445
[TBL] [Abstract][Full Text] [Related]
20. Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody.
Rice DC; Chapoval AI; Porter L; Nelson H
Cancer Immunol Immunother; 1999 Aug; 48(5):230-8. PubMed ID: 10478639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]